Related Experiment Video
Updated: Mar 8, 2026
Small Molecule Screening and Toxicity Testing in Early-stage Zebrafish Larvae
Published on: March 7, 2025
In Vitro Biotransformation of Two Human CYP3A Probe Substrates and Their Inhibition during Early Zebrafish
Evy Verbueken1, Derek Alsop2, Moayad A Saad3
1Applied Veterinary Morphology, Department of Veterinary Sciences, University of Antwerp, 2610 Wilrijk, Antwerp, Belgium. evy.verbueken@uantwerpen.be.
Abstract:
At present, the zebrafish embryo is increasingly used as an alternative animal model to screen for developmental toxicity after exposure to xenobiotics. Since zebrafish embryos depend on their own drug-metabolizing capacity, knowledge of their intrinsic biotransformation is pivotal in order to correctly interpret the outcome of teratogenicity assays. Therefore, the aim of this in vitro study was to assess the activity of cytochrome P450 (CYP)-a group of drug-metabolizing enzymes-in microsomes from whole zebrafish embryos (ZEM) of 5, 24, 48, 72, 96 and 120 h post-fertilization (hpf) by means of a mammalian CYP substrate, i.e., benzyloxy-methyl-resorufin (BOMR). The same CYP activity assays were performed in adult zebrafish liver microsomes (ZLM) to serve as a reference for the embryos. In addition, activity assays with the human CYP3A4-specific Luciferin isopropyl acetal (Luciferin-IPA) as well as inhibition studies with ketoconazole and CYP3cide were carried out to identify CYP activity in ZLM. In the present study, biotransformation of BOMR was detected at 72 and 96 hpf; however, metabolite formation was low compared with ZLM. Furthermore, Luciferin-IPA was not metabolized by the zebrafish. In conclusion, the capacity of intrinsic biotransformation in zebrafish embryos appears to be lacking during a major part of organogenesis.
Insights
Zebrafish embryos show limited drug metabolism during early development, impacting their use in toxicity testing. This study assessed cytochrome P450 (CYP) activity, finding low biotransformation capacity in embryos compared to adults.
Area of Science:
- Pharmacology
- Developmental Biology
- Toxicology
Background:
- Zebrafish embryos are a model for xenobiotic developmental toxicity screening.
- Understanding zebrafish drug metabolism is crucial for interpreting toxicity assay results.
Purpose of the Study:
- To assess cytochrome P450 (CYP) enzyme activity in zebrafish embryos (ZEM) at various developmental stages (5-120 hpf).
- To compare embryonic CYP activity with adult zebrafish liver microsomes (ZLM).
- To identify specific CYP activities using mammalian and human substrates.
Main Methods:
- In vitro enzyme assays using benzyloxy-methyl-resorufin (BOMR) and Luciferin isopropyl acetal (Luciferin-IPA) substrates.
- Microsomal preparations from whole zebrafish embryos (ZEM) and adult zebrafish liver (ZLM).
- Inhibition studies with ketoconazole and CYP3cide in ZLM.
Main Results:
- BOMR biotransformation was detected in ZEM at 72 and 96 hpf, but metabolite formation was low compared to ZLM.
- Luciferin-IPA, a human CYP3A4 substrate, was not metabolized by zebrafish.
- CYP activity in ZLM was confirmed and characterized using specific inhibitors.
Conclusions:
- Zebrafish embryos exhibit limited intrinsic drug-metabolizing capacity, particularly cytochrome P450 activity, during early organogenesis.
- This lack of metabolic capability may affect the reliability of developmental toxicity studies using zebrafish embryos.
- Further research is needed to understand the full implications for xenobiotic risk assessment.
